

## SAFETY DATA SHEET



GlaxoSmithKline

### \* 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

<b>Material</b>	<b>BC HEADACHE POWDER</b>
<b>Synonym(s)</b>	BC HEADACHE POWDER (US) * FORMULA NO. B0006 * BC ANALGESIC POWDER * ASPIRIN, CAFFEINE AND SALICYLAMIDE, FORMULATED PRODUCT
<b>Company Name</b>	<p>GlaxoSmithKline, Corporate Environment, Health &amp; Safety 980 Great West Road Brentford, Middlesex TW8 9GS UK</p> <p>UK General Information: +44-20-8047-5000 Transport Emergency (EU) +44-1865-407333 Medical Emergency +1-612-221-3999, Ext 221 Information and Advice: US number, available 24 hours Multi-language response</p> <p>GlaxoSmithKline, Corporate Environment, Health &amp; Safety One Franklin Plaza, 200 N 16th Street Philadelphia, PA 19102-1225 US</p> <p>US General Information: +1-888-825-5249 Transport Emergency (non EU) +1-703-527-3887 US number, available 24 hours Multi-language response</p>

### \* 2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS #	Percent	EC-No.
ASPIRIN	50-78-2	56	
CAFFEINE	58-08-2	<3	
SALICYLAMIDE	65-45-2	17	
Other components below reportable levels		24	

### 3. HAZARDS IDENTIFICATION

<b>Fire and Explosion</b>	Assume that this product is capable of sustaining combustion.
<b>Health</b>	<p>Eye irritant. Exposure might occur via eyes; skin; ingestion. Possible effects of overexposure in the workplace include: symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing) Health effects information is based on hazards of components.</p>
<b>Environment</b>	No information is available about the potential of this product to produce adverse environmental effects.

Material BC HEADACHE POWDER

## 4. FIRST-AID MEASURES

<b>Ingestion</b>	Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
<b>Inhalation</b>	Using appropriate personal protective equipment, move exposed subject to fresh air. If breathing is difficult or ceases, ensure and maintain ventilation. Give oxygen as appropriate. The exposed subject should be kept warm and at rest. Obtain medical attention in cases of known or possible over exposure, or with symptoms including chest pain, difficulty breathing, loss of consciousness or other adverse effects, which may be delayed.
<b>Skin Contact</b>	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.
<b>Eye Contact</b>	Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

### NOTES TO HEALTH PROFESSIONALS

<b>Medical Treatment</b>	Medical treatment in cases of overexposure should be treated as an overdose of aspirin . Treat according to locally accepted protocols. For additional guidance, refer to the local poison control information centre.
<b>Medical Conditions Caused or Aggravated by Exposure</b>	None for occupational exposure.
<b>Antidotes</b>	No specific antidotes are recommended.

## 5. FIRE-FIGHTING MEASURES

<b>Fire and Explosion Hazards</b>	The combustibility of the product is not known, however the packaging is combustible.
<b>Extinguishing Media</b>	Water, dry powder or foam extinguishers are recommended. Carbon dioxide extinguishers may be ineffective.
<b>Special Firefighting Procedures</b>	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.
<b>Hazardous Combustion Products</b>	Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

## 6. ACCIDENTAL RELEASE MEASURES

<b>Personal Precautions</b>	Wear protective clothing and equipment consistent with the degree of hazard.
<b>Environmental Precautions</b>	For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.
<b>Clean-up Methods</b>	Collect and place it in a suitable, properly labelled container for recovery or disposal.
<b>Decontamination Procedures</b>	No specific decontamination or detoxification procedures have been identified for this product.

## 7. HANDLING AND STORAGE

### HANDLING

**General Requirements** Normal room ventilation is expected to be adequate for routine handling of this product.

### STORAGE

No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

Material BC HEADACHE POWDER

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<b>INGREDIENT</b>	CAFFEINE
<b>GSK Occupational Hazard Category</b>	2
<b>GSK Occupational Exposure Limit</b>	200 mcg/m <sup>3</sup> (8 HR TWA)
<b>INGREDIENT</b>	ASPIRIN
<b>GSK Occupational Hazard Category</b>	1
<b>GSK Occupational Exposure Limit</b>	3000 mcg/m <sup>3</sup> (8 HR TWA)

## 9. PHYSICAL AND CHEMICAL PROPERTIES

### Appearance

<b>Colour</b>	White.
<b>Physical Form</b>	Powder.
<b>Packaging</b>	Glassine envelopes.

## 10. STABILITY AND REACTIVITY

<b>Stability</b>	This product is expected to be stable.
<b>Conditions to Avoid</b>	None for normal handling of this product.

## 11. TOXICOLOGY INFORMATION

<b>Pharmacological Effects</b>	This product contains active ingredient(s) with the following activity: a non-steroidal anti-inflammatory substance.
<b>Target Organ Effects</b>	Adverse effects might occur in the following organ(s) following overexposure: impaired blood coagulation.
<b>Routes of Exposure</b>	
<b>Oral Toxicity</b>	Toxicity might occur following ingestion.
<b>Inhalation Toxicity</b>	No studies have been conducted. Overexposure may result in irritation of the respiratory tract.
<b>Skin Effects</b>	Irritation might occur following direct contact.
<b>Eye Effects</b>	Irritation might occur following direct contact with eyes.
<b>Sensitisation</b>	Sensitisation (allergic skin reaction) is not expected.
<b>Genetic Toxicity</b>	Not expected to be genotoxic under occupational exposure conditions.
<b>Carcinogenicity</b>	No components are listed as carcinogens by GSK, IARC, NTP or US OSHA. Not expected to produce cancer in humans under occupational exposure conditions.
<b>Reproductive Effects</b>	No adverse effects have been reported following extensive use or exposure in humans.
<b>Other Adverse Effects</b>	Overexposure in the workplace might have the following effects: impaired blood coagulation; symptoms of hypersensitivity (such as skin rash, hives, itching, and/or difficulty breathing).

## 12. ECOLOGICAL INFORMATION

<b>Summary</b>	This material contains an active pharmaceutical ingredient that has been tested, and no environmental effects have been identified. Local regulations and procedures should be consulted prior to environmental release.
----------------	--

## 13. DISPOSAL CONSIDERATIONS

<b>Disposal Recommendations</b>	Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.
---------------------------------	---

**Regulatory Requirements** Observe all local and national regulations when disposing of this product.

## 14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

### UN Classification and Labelling

**Transport Information** Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes.

## 15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

### EU Classification and Labelling

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

### US OSHA Standard (29 CFR Part 1910.1200)

**Classification** Exempt when packaged for sale to consumers in a retail establishment.

### Other US Regulations

**TSCA Status** Exempt

## 16. OTHER INFORMATION

**References** GSK Hazard Determination

**SDS Version Number** 7

### SDS Sections Updated

#### Sections

COMPOSITION / INFORMATION ON INGREDIENTS

IDENTIFICATION OF SUBSTANCE / PREPARATION AND OF COMPANY

#### Subsections

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.